Acquiring Company
Siegfried
Acquired Company
Extractas Bioscience
Zofingen
TasmaniaManufacturingBiotechnologyPharmaceuticalManufacturingBiotechnologyDescription
Siegfried AG has completed the acquisition of three drug substance sites in the US and Australia effective May 1, 2026. This strategic acquisition strengthens Siegfried's manufacturing capabilities and is expected to contribute approximately USD 100 million in net sales for 2026. The integration of the new sites is progressing smoothly, enhancing the company's capacity to support early-phase development to commercial manufacturing. Siegfried continues to execute its growth strategy while focusing on operational excellence.
Quick answer
Siegfried is acquiring Extractas Bioscience, announced May 1, 2026. Siegfried is based in Zofingen, Aargau, Switzerland.
- How much did Siegfried pay for Extractas Bioscience?
- The deal value was not disclosed.
- What does Siegfried do?
- Expect more with Siegfried as your preferred partner.
- Where are Siegfried and Extractas Bioscience based?
- Siegfried is based in Zofingen, Aargau, Switzerland. Extractas Bioscience is based in Tasmania, Australia.
- Who are the decision-makers at Siegfried?
- Fundz holds 3 contacts at Siegfried. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Pharmaceutical and Manufacturing
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- ESTEVE acquires TerSera's Infusion Business Unit (May 4, 2026)
- Merck acquires JSR Life Sciences' chromatography business (April 2, 2026)
- Jubilant Ingrevia acquires Remidex Pharma completely (March 30, 2026)
- GSK to acquire Nuvalent for $10.6 billion, $11B (June 9, 2026)
- Anupam Rasayan to acquire majority in Bliss GVS (May 23, 2026)
- Gujarat Themis Biosyn to Acquire MicroBiopharm Japan (May 22, 2026)
Who to call at Siegfried, and when
When Siegfried changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Siegfried raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Siegfried, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Siegfried. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Siegfried makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Extractas Bioscience?
Extractas Bioscience was acquired by Siegfried, based in Zofingen. The deal was reported on May 1, 2026. Expect more with Siegfried as your preferred partner. Siegfried is a preferred manufacturing and service partner in the global pharmaceutical industry. Siegfried is privately held and operates in Manufacturing.
When did Siegfried acquire Extractas Bioscience?
Siegfried's acquisition of Extractas Bioscience was reported on May 1, 2026. Siegfried AG has completed the acquisition of three drug substance sites in the US and Australia effective May 1, 2026. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Extractas Bioscience do?
Extractas Bioscience specializes in the extraction and processing of high-quality plant-derived substances for pharmaceutical applications. The company contributes several technological and operational capabilities that enhance drug substance manufacturing. It is privately held, operating in Manufacturing, and is based in Tasmania.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.